论文部分内容阅读
将８８例心室晚电位（ＶＬＰ）阳性的室性心律失常（ＶＡ）患者随机分为Ａ、Ｂ两组，分别服倍他乐克及莫雷西嗪，四周后复查２４小时动态心电图（ＤＣＧ）及ＶＬＰ。结果表明：莫雷西嗪虽能有效控制ＶＡ（３３／４２），但不能使ＶＬＰ转阴，且有促心律失常作用（３／４２），而倍他乐克不但能较好控制ＶＡ（３８／４６），且可使阳性的ＶＬＰ逆转（３９／４６），又无促心律失常及其它明显副作用。后者用量为５０～１００ｍｇ／ｄ时剂量与疗效之间无明显关系。作者认为，对ＶＬＰ阳性的ＶＡ考虑药物治疗时，只要无应用β－受体阻滞剂的禁忌证，可首选倍他乐克。
Eighty-eight patients with ventricular late-ventricular (VLP) -positive ventricular arrhythmias (VA) were randomly divided into A and B groups and received metoprolol and meticillin respectively. After 24 weeks, 24-hour ambulatory electrocardiogram (DCG) And VLP. The results showed that, although effective in controlling VA (33/42), methicillin failed to turn negative VLP and had arrhythmogenic effect (3/42), and metoprolol not only controlled VA (38 / 46) and reversed the positive VLP (39/46) without proarrhythmic and other significant side effects. The latter dose of 50 ~ 100mg / d no significant relationship between dose and efficacy. The author believes that for the VLP-positive VA consider drug treatment, as long as there is no contraindication for β-blockers, the preferred choice of metoclei.